Tesamorelin vs sermorelin: how the two GH peptides compare
Tesamorelin and sermorelin both act on the growth hormone-releasing hormone (GHRH) receptor, but they are not the same molecule or the same regulatory target. As a physician who has taught the growth hormone secretagogue material in the A4M Peptide Therapy Mastery course, I read the tesamorelin vs sermorelin question through three lenses: structure, half-life, and approval status. Sermorelin is a 29-amino-acid fragment of GHRH; tesamorelin is the full 44-amino-acid sequence stabilized against enzymatic breakdown. That difference drives everything below.
Tesamorelin vs. Sermorelin: What is the difference?
The difference starts with the sequence. Sermorelin is GRF(1-29), the first 29 amino acids of human GHRH, amidated at the C-terminus. That fragment is the shortest segment of GHRH that still binds to and activates the receptor, which is why it serves as a research analog [1]. Tesamorelin is built differently: it retains the full 44-amino-acid GHRH sequence and adds a trans-3-hexenoic acid group to the tyrosine at the amino terminus [2]. Both bind the same GHRH receptor on pituitary somatotroph cells, where activation raises intracellular cyclic AMP and prompts the cell to release stored growth hormone, as described in a review of growth hormone secretagogues [3].
So the shared mechanism is real, but the marketing shorthand calling them interchangeable is not. One is a truncated native fragment; the other is a stabilized full-length analog with a synthetic cap. The published research on each was generated under that structural reality, and a research-use comparison of the peptide Tesamorelin against sermorelin has to start there rather than with a list of claimed benefits.
How do their half-lives and stability compare?
Stability is where the structural difference shows up most clearly. Native GHRH is cleaved within minutes by dipeptidyl peptidase-4 (DPP-4), an enzyme that clips peptides at the second amino acid. Sermorelin inherits that vulnerability: a clinical pharmacokinetic study measured the intravenous half-life of GHRH(1-29) at about 4 minutes, with high metabolic clearance [4]. Product pharmacology summaries indicate a slightly longer duration of roughly 11-12 minutes via the subcutaneous route, but the peptide still clears quickly. The hexenoyl cap on tesamorelin blocks DPP-4 access, and the reported half-life increases to about 26-38 minutes [2]. Sermorelin is the less stable of the two by design, because it is the smaller fragment.
| Property | Sermorelin | Tesamorelin |
| Structure | GRF(1-29) fragment, amidated | Full GHRH(1-44) plus trans-3-hexenoic acid cap |
| Reported half-life | ~4 minutes IV; ~11 to 12 minutes by product summaries [4] | ~26 to 38 minutes [2] |
| DPP-4 resistance | No (cleaved rapidly) | Yes (hexenoyl cap blocks cleavage) [2] |
| Receptor | GHRH receptor [3] | GHRH receptor [3] |
| FDA-approved analog | No | Yes, as a clinical formulation [5] |
Half-life is not the same as the duration of effect. Sermorelin’s growth-hormone-stimulating signal in the published work can persist beyond its short plasma half-life because the pituitary response outlasts the peptide [1]. Stability still matters for handling, which is why purity and identity testing through an in-house analytical chemistry program underpins any reproducible research result.
Why is tesamorelin the only FDA-approved GHRH analog?
Tesamorelin is the only GHRH analog approved by the FDA. It was approved in 2010 as Egrifta for HIV-associated lipodystrophy, and a reformulated version, Egrifta WR, was approved in March 2025 [5]. The approval rests on Phase III data: in the registration trial of 412 patients, published in the *New England Journal of Medicine*, tesamorelin 2 mg administered by daily subcutaneous injection reduced visceral adipose tissue by about 15 percent relative to placebo over 26 weeks [6]. A later randomized trial in *JAMA* reported reduced liver fat on the same dose [7]. Important distinction, and one I keep sharp when I teach this: the FDA-approved Egrifta formulation is a finished clinical drug, separate from the research-grade tesamorelin peptide supplied for in vitro study—the two share a molecule, not a regulatory status.
Sermorelin has its own regulatory history. It was FDA-approved as Geref, used in growth-hormone-deficiency assessment, then discontinued in 2008 for commercial rather than safety reasons, which is why it is no longer an approved product [8]. In my own review of growth hormone secretagogues, I traced how approval status, rather than biological interest, has shaped which of these peptides have accumulated large trial datasets [9]. Approval status frames the evidence base; it does not rank the molecules.
What does each peptide’s research actually study?
The two literatures point in different directions. Sermorelin research centers on the pituitary growth-hormone axis itself, particularly age-related decline, because the fragment stimulates the gland to release its own growth hormone while preserving somatostatin negative feedback, which is the feature that distinguishes a secretagogue from injected recombinant growth hormone [1]. That is the substance behind the common sermorelin-versus-HGH framing: somatropin is exogenous growth hormone, whereas sermorelin prompts endogenous release. My clinical observation work on sermorelin falls within the context of research on age-related decline [10].
Tesamorelin research is dominated by body-composition endpoints, specifically visceral adipose tissue and hepatic fat, the endpoints around which its trials were designed [6][7]. For the broader growth hormone peptide category, that split is the practical takeaway: the question is rarely which peptide is better in the abstract, but which research model a given study is built to address. None of these findings is human-use guidance; they are research measurements from defined study populations, framed for laboratory work.
References
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. DOI: 10.2147/ciia.2006.1.4.307. PMID: 18046908.
- Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV/AIDS (Auckland). 2011;3:69-79. DOI: 10.2147/HIV.S14561. PMID: 22096409.
- Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. DOI: 10.1002/rco2.9.
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Journal of Clinical Endocrinology and Metabolism. 1994;79(4):1208-1211. DOI: 10.1210/jcem.79.4.7962295. PMID: 7962295.
- Theratechnologies Inc. FDA approval of EGRIFTA WR (tesamorelin F8) for excess visceral abdominal fat in adults with HIV and lipodystrophy. Press and regulatory record; 2025 March 25.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. DOI: 10.1056/NEJMoa072375. PMID: 18057338.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. DOI: 10.1001/jama.2014.8334. PMID: 25038357.
- S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register. 2013;78(42):14122-14123.
- Patterson M, Reeves K. Growth hormone secretagogues in anti-aging medicine: review of current evidence and clinical applications. International Journal of Anti-Aging Medicine. 2020;17(3):145-159.
- Patterson M. Sermorelin and ipamorelin for age-related growth hormone decline: clinical observations from a cash-pay practice. Anti-Aging Medical Therapeutics. 2022;9(1):34-47.
Research Use Only Disclaimer
Healius Peptides products are sold for in vitro research use only and are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
Frequently Asked Questions About GHRH Peptides
Yes, as a clinical formulation. Tesamorelin is the only GHRH analog approved by the FDA, marketed as Egrifta (2010) and Egrifta WR (2025) for the treatment of HIV-associated lipodystrophy [5]. That approval applies to the finished prescription drug. The research-grade tesamorelin peptide is a separate product supplied for in vitro research use only, not the approved clinical formulation.
Sermorelin was previously FDA-approved as Geref for the assessment of growth hormone deficiency. Still, the manufacturer discontinued it in 2008 for commercial reasons, so it is no longer an approved product [8]. Research-grade sermorelin is currently supplied as a peptide for in vitro studies, not as an approved medicine.
No. HGH, or somatropin, is recombinant human growth hormone given directly. Sermorelin is a GHRH receptor analog that prompts the pituitary to release its own growth hormone while preserving the gland’s negative feedback control [1]. In published research, the two act through different mechanisms and are not interchangeable.
Sermorelin is a growth hormone-releasing hormone analog, specifically the GRF(1-29) fragment of human GHRH [1]. It is a peptide, not a steroid, and not a hormone replacement. It acts upstream of growth hormone by signaling the pituitary gland, rather than supplying a hormone itself.
Lyophilized peptides are typically stored frozen until use, and once reconstituted, peptide solutions are generally held at 2 to 8 degrees Celsius to limit degradation. Because storage conditions affect peptide integrity, a certificate of analysis and proper handling matter for reproducible research results. Healius peptides are supplied for in vitro research use only.
In the published trials, body-composition endpoints were measured over months, not days. The headline visceral-fat result was reported at 26 weeks of daily 2 mg dosing, and liver-fat reductions were reported over comparable durations [6][7]. These are study timelines from defined research populations, not human-use recommendations.
Leave a Reply